Y-27632 dihydrochloride: Selective ROCK Inhibitor for Advanced Cell and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a cell-permeable, small-molecule inhibitor with high selectivity for Rho-associated protein kinases ROCK1 and ROCK2, exhibiting IC₅₀ values near 140 nM and a Ki of 300 nM, respectively (APExBIO). It demonstrates over 200-fold selectivity versus kinases such as PKC, PKA, MLCK, and PAK, minimizing off-target effects. In vitro, Y-27632 disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and inhibits cytokinesis (see detailed mechanism). Preclinical studies confirm its ability to enhance stem cell viability and suppress tumor invasion and metastasis in animal models. Its robust solubility profile and stability make it indispensable for reproducible cell signaling research.

Biological Rationale

The Rho/ROCK signaling pathway orchestrates actin cytoskeleton dynamics, cell motility, contraction, and proliferation (Mishra et al., 2024). Dysregulation of ROCK activity is linked to tumor invasion, metastasis, and abnormal cell division. ROCK1 and ROCK2 are serine/threonine kinases activated by the small GTPase RhoA. Their downstream effectors include myosin light chain (MLC) and LIM kinase, pivotal in stress fiber and focal adhesion assembly. Pharmacological inhibition of ROCK kinases using highly selective compounds like Y-27632 dihydrochloride enables the study of these cellular processes with minimal confounding by off-target kinase inhibition. This approach is critical for dissecting mechanisms in stem cell biology, cancer research, and neurodegenerative disease models (see neuro-epithelial context).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds selectively to the catalytic domains of ROCK1 and ROCK2, inhibiting ATP-dependent phosphorylation of downstream targets. The compound exhibits an IC₅₀ of ~140 nM against ROCK1 and a Ki of 300 nM for ROCK2, with >200-fold selectivity over kinases PKC, PKA, MLCK, and PAK (APExBIO). This selectivity profile is established by in vitro kinase assays. Inhibition of ROCK activity by Y-27632 leads to:

• Disruption of actin stress fiber formation and focal adhesion assembly.
• Suppression of myosin light chain phosphorylation, reducing contractility.
• Alteration of the cell cycle by modulating G1/S progression and cytokinesis.
• Reduced cell motility and invasion, pertinent to tumor metastasis models.

This mechanism enables precise manipulation of the Rho/ROCK pathway for experimental dissection (compare with troubleshooting guide).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of approximately 140 nM in biochemical assays (APExBIO).
• Shows >200-fold selectivity over PKC, PKA, MLCK, and PAK, minimizing off-target kinase inhibition (APExBIO).
• Reduces proliferation of prostatic smooth muscle cells in vitro in a concentration-dependent manner (10–50 μM, 24–72 h, DMEM, 37°C) (APExBIO).
• In mouse xenograft models, Y-27632 administration decreases tumor invasion and metastasis (20 mg/kg, i.p., daily for 2 weeks) (see advanced cancer research).
• Enhances viability and expansion of human-induced pluripotent stem cells (hiPSCs) under feeder-free conditions (10 μM, 24–48 h, mTeSR1 medium) (see translational perspective).
• Solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water at 25°C; heating to 37°C or ultrasonic bath improves dissolution (APExBIO).
• Stock solutions are stable below -20°C for several months; solid form should be stored desiccated at 4°C or below (APExBIO).
• No evidence of significant inhibition of endosomal trafficking in hiPSC-derived neurons or microglia, differentiating its mode of action from SORL1 or presenilin pathway modulators (Mishra et al., 2024).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is utilized for:

• Cytoskeletal research: Dissects actin-myosin regulation and cellular contractility.
• Stem cell biology: Enhances survival and cloning efficiency of embryonic and induced pluripotent stem cells, especially following single-cell dissociation.
• Cancer research: Suppresses tumor invasion and metastasis in vivo; used as a benchmark control for Rho/ROCK pathway studies.
• Cell proliferation assays: Quantifies effects on cell cycle progression and cytokinesis.
• Neurodegeneration models: Used to modulate cytoskeletal integrity, but does not directly influence endo-lysosomal trafficking or SORL1-related mechanisms (Mishra et al., 2024).

This article extends prior coverage by providing explicit solubility, selectivity, and storage parameters for reproducibility, building on the mechanistic focus of Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal Studies.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: Y-27632 selectively inhibits ROCK1/2 but shows minimal activity on other kinases such as MLCK, PKA, or PKC.
• Does not directly modulate endosomal or lysosomal trafficking: Its mechanism is distinct from agents targeting SORL1 or presenilin pathways (Mishra et al., 2024).
• Long-term solution storage not recommended: Stock solutions are stable for months at -20°C, but repeated freeze-thaw cycles or room temperature exposure may decrease potency.
• Concentration-dependent effects: Optimal working concentrations must be empirically determined; high doses (>50 μM) may induce cytotoxicity in sensitive lines.
• Not suitable for in vivo ROCK-independent pathway studies: Off-target or compensatory mechanisms may confound interpretation in complex disease models.

Workflow Integration & Parameters

Y-27632 dihydrochloride (APExBIO, A3008) is supplied as a solid, to be stored desiccated at 4°C or below. For stock preparation, dissolve to ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water, optionally warming to 37°C or using an ultrasonic bath for complete dissolution. Aliquot and store stock at -20°C to avoid repeated freeze-thaw cycles. In typical cell-based protocols:

• For stem cell viability: add 10 μM Y-27632 to culture media for 24–48 h post-passage.
• For cytoskeletal studies: treat cells with 10–50 μM for 1–24 h, monitor by phalloidin staining.
• For in vivo tumor models: administer 20 mg/kg intraperitoneally, daily for defined periods (consult IACUC guidelines).

Care should be taken to validate batch-to-batch consistency and match experimental controls. For workflows integrating endo-lysosomal pathway studies or SORL1-deficiency models, Y-27632 does not replicate effects seen with endosomal trafficking modulators (Mishra et al., 2024).

For more detailed experimental integration, this comparison article offers troubleshooting strategies for optimizing Rho/ROCK pathway inhibition, which are complemented here with quantitative solubility and selectivity data.

Conclusion & Outlook

Y-27632 dihydrochloride has established itself as the reference selective ROCK inhibitor for cytoskeletal, stem cell, and cancer research. Its high potency, defined selectivity, and reliable solubility/storage characteristics enable reproducible and interpretable experiments. While not a tool for modulating endo-lysosomal trafficking or SORL1-dependent pathways, it remains indispensable for dissecting the Rho/ROCK axis in cell biology and disease modeling. Researchers seeking to target alternative cellular pathways should consider pathway-relevant inhibitors. For Rho/ROCK pathway studies, Y-27632 dihydrochloride from APExBIO is a validated, high-performance option.